Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Toxicology and Applied Pharmacology|August 30, 2008
In silico identification of anthropogenic chemicals as ligands of zebrafish sex hormone binding globulinNels Thorsteinson, Fuqiang Ban, Osvaldo Santos-Filho, et al.
Scientific Reports|February 2, 2026
Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infectionJason R Smith, Ayelen Toro, Agustina Sabater, et al.
International Journal of Molecular Sciences|March 10, 2022
Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate CancerAnh-Tien Ton, Jane Foo, Kriti Singh, et al.
Pharmaceuticals (Basel, Switzerland)|November 18, 2020
Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate CancerOscar Ekpenyong, Candace Cooper, Jing Ma, et al.
Breast Cancer Research : BCR|November 27, 2024
Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2)Jane Foo, Francesco Gentile, Shabnam Massah, et al.
European Journal of Medicinal Chemistry|September 8, 2018
Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptorKush Dalal, Helene Morin, Fuqiang Ban, et al.
Cells|September 23, 2022
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor InhibitorsMariia Radaeva, Huifang Li, Eric LeBlanc, et al.
Nature Communications|November 19, 2020
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing siteJaeyong Lee, Liam J Worrall, Marija Vuckovic, et al.
European Journal of Medicinal Chemistry|October 17, 2018
Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancerLavinia A Carabet, Nada Lallous, Eric Leblanc, et al.
The Journal of Biological Chemistry|August 3, 2014
Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancerKush Dalal, Mani Roshan-Moniri, Aishwariya Sharma, et al.
Pageof 7